ReviewInternational journal of nanomedicine2026
A Comprehensive Review of Vitamin C for Cancer Therapy: Anti-Tumor Mechanisms and Nano-Formulation Strategies.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid advancements in nanotechnology have provided unprecedented opportunities for the clinical translation of vitamin C (VC) in cancer therapy. Although pharmacological doses of VC exhibit potent anti-tumor activities via multiple mechanisms-including selective pro-oxidative stress induction, metabolic inhibition, epigenetic modulation, and immune function enhancement-the clinical application of VC remains significantly hindered by its inherent instability, short biological half-life, and lack of tumor-specific targeting. Recent progress in the design and synthesis of VC and its derivatives combined with advanced nanocarriers has enabled precise delivery and efficient release of VC at tumor sites. In this review, we systematically summarize recent advances in nano-formulation strategies of VC, with a detailed discussion of lipid-based nanocarriers including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric nanoparticles, as well as metal-based nanozyme delivery systems primarily composed of iron, copper, and manganese. These nano-systems not only significantly enhance the stability and circulation half-life of VC but also exploit tumor microenvironment-specific stimuli, such as pH, hydrogen peroxide (H
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.